Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on March 23, 2015, reporting the entry into a material definitive agreement. Specifically, the company secured a $750 million senior unsecured five-year revolving credit facility on March 19, 2015. This facility, with a maturity date of March 19, 2020, provides significant financial flexibility for working capital needs and general corporate purposes. The Credit Agreement includes provisions for potential increases in commitments or the addition of term loans up to $250 million, subject to lender consent and other conditions. While the facility carries variable interest rates, it also includes standard financial and operating covenants, such as limitations on leverage, debt incurrence, and asset disposition. Importantly, as of the filing date, no amounts were outstanding under this new credit facility, indicating the company is proactively securing resources without immediate borrowing needs.
Key Highlights
- 1Regeneron secured a $750 million senior unsecured five-year revolving credit facility effective March 19, 2015.
- 2The credit facility has a maturity date of March 19, 2020.
- 3Proceeds can be used for working capital and general corporate purposes.
- 4The agreement allows for potential expansion of credit lines or term loans up to an additional $250 million.
- 5Interest rates are variable, based on LIBOR or alternate base rate plus an applicable margin.
- 6The facility includes standard financial covenants (leverage, interest coverage) and operating covenants (debt, liens, asset sales).
- 7No amounts were outstanding under the credit facility as of the filing date.